CG
LVTX

Colony Group’s LAVA Therapeutics LVTX Stock Holding History

Colony Group’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$35K – 835
2022
Q4 		$35K Buy
+10,000
New +$45.9K ﹤0.01% 823

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Colony Group's LVTX Position: Q1 2023 in Review

Colony Group sold out of LAVA Therapeutics (LVTX) in Q1 2023, closing a stake of 10,000 shares — an estimated $35K sold.

Colony Group first reported a position in LVTX in Q4 2022 and held it in 1 quarter. The position peaked at $35K in Q4 2022. 19 funds tracked by Wall St. Rank hold LVTX as of Q1 2023.

  • Colony Group reported no remaining LAVA Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Colony Group sold 10,000 LAVA Therapeutics shares in Q1 2023, an estimated $35K.
  • Colony Group first reported a position in LAVA Therapeutics in Q4 2022 and held it in 1 quarter.
  • Colony Group's LAVA Therapeutics position peaked at $35K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2023.

Based on Colony Group's 13F filing for Q1 2023, filed 16 May 2023.